161 results about "Bladder cancer cell" patented technology

The invention discloses a method for carrying out gene editing and expression regulation by utilizing a Cas splitting system. A protein group is provided for splitting a Cas9 protein amino acid sequence from different sites to form two-section proteins which form a protein group. Proved by an experiment, an Intein-mediated Ca9 splitting system can efficiently realize gene editing and transcriptional activation regulation on a gene circuit. According to the method disclosed by the invention, the CaS9 splitting system is combined with a tumor cell specific promoter, so that specific detection can be carried out on bladder cancer cells.

The invention discloses a bladder cancer screening detection kit which is capable of recognizing PVT1 genes specifically. The bladder cancer screening detection kit has the advantages that PVT1 is highly expressed in bladder cancer cells, and by means of detecting the PVT1 genes, early screening of the bladder cancer can be achieved; tetracycline-induced PVT1 shRNA (short hairpin ribonucleic acid) is capable of knocking out PVT1 expression effectively, inhibiting bladder cancer cell multiplication and promoting bladder cancer cell apoptosis so as to make bladder cancer diagnosis and treatment possible.

The invention provides application of target up-regulation PAR-4 gene small ribonucleic acid (RNA) in preparing bladder cancer resisting drugs. The nucleotide sequence of the target up-regulation PAR-4 gene small RNA is composed of six positive sense strands and negative sense strands of 21 nucleotides. The 3' end of each strand is provided with two nucleotides in suspension mode (generally dTdT, and the 19 nucleotides in the middle are paired.). The target up-regulation PAR-4 gene small RNA comprises sa RNA of different sequences. By means of expression of target up-regulation PAR-4 genes in the bladder cancer cells, the small RNA can restrain tumor cell activity, induces cell apoptosis, and further can be applied to preparation of bladder cancer resisting drugs. The application of target up-regulation PAR-4 gene small RNA in preparing the bladder cancer resisting drugs is simple in operation of preparing the small RNA, low in cost, small in using amount, capable of achieving good activation effect when the transfection concentration is 50nM and accurate in activation action. The mRNA and protein level of the target genes are both improved. In addition, the sa RNA can induce genes to express without damaging completeness of gene groups, thereby being safe to use.

The invention belongs to the field of biotechnology, and specifically relates to miR-411 as a bladder cancer target and its application. The invention uses bladder cancer T24 and UMUC3 cells as models, and overexpressing miR-411 can inhibit the proliferation of bladder cancer cells in vivo and in vitro, and induce bladder cancer Cancer cell cycle G2 / M phase arrest, while enhancing the sensitivity of chemotherapy drugs (mitomycin and gemcitabine) to bladder cancer cells. It can be seen that miR-411 expression promoter can prevent or / and treat bladder cancer. Using miRNA chip technology, real-time fluorescent quantitative PCR technology, bioinformatics analysis of TCGA database and other methods to detect the expression of miR‑411 in bladder cancer primary animal models and clinical bladder cancer tissues showed a significant down-regulation trend, and the expression of miR‑411 was correlated with bladder cancer There is a certain positive correlation with the survival time of patients. It can be seen that by detecting the expression of miR‑411, bladder cancer can be assisted in the diagnosis and / or prognosis.

The invention provides application for directionally killing cisplatin-resistant human bladder cancer cells T24 / DDP through a coupling CD3*B7H3 dual-specificity antibody, particularly, the coupling CD3*B7H3 dual-specificity antibody can enhance the T24 / DDP cisplatin-resistant bladder cancer cell killing effect of the activated T cell (ATC), and an immunity treatment target spot is provided for bladder cancer drug-resistant targeting treatment. Researches prove that B7H3 can achieve high expression in the T24 / DDP cisplatin-resistant bladder cancer cell; compared with the ATC of the uncoupled CD3*B7H3 dual-specificity antibody, the capability of the ATC combined with the CD3*B7H3 dual-specificity antibody for directionally killing the T24 / DDP cisplatin-resistant bladder cancer cells is enhanced, and the remarkable cell toxin activity is achieved for the T24 / DDP cisplatin-resistant bladder cancer cells. When co-culture is performed on the condition that the effective target ratio of the ATC combined with the CD3*B7H3 dual-specificity antibody to the tumor cells is 10:1, the killing effect is remarkably increased. Meanwhile, the level of the ATC combined with the CD3*B7H3 dual-specificity antibody for secreting a gamma-interferon (IFN-gamma) and an alpha-tumor necrosis factor (TNF-alpha) is increased.

A trans-epithelial appliance having a hemidesmosome formation-inducing protein composition derived from rat bladder carcinoma cells deposited thereon. This composition stimulates cell attachment and may be either the cell matrix or a soluble factor isolated from the conditioned medium. The appliance will be useful for diminishing inflammation and / or infection at the site of entry of the appliance. The appliance may also be used to stimulate gum junctional epithelium adhesion in the treatment of gingivitis and periodontitis. The composition may be used to maintain tissues ex vivo.

The invention provides copy number amplification of the FRS2 gene, applications of the copy number amplification, and specific primer pairs for detecting the copy number amplification, and belongs tothe field of biotechnologies. The number of times for copy number amplification is 3 or more. The density of the new blood vessels in the bladder cancer sample after the copy number amplification is high. In the bladder cancer cell line cultured in vitro, specific siRNA is utilized for interfering the expression of FRS2, so that the capacity of recruiting the vascular endothelial cells of the bladder cancer cells and the capacity of inducing the vascular endothelial cells to form tubules of the bladder cancer cells are inhibited. The invention further provides the applications of the copy number amplification of the FRS2 gene in preparing kits for detecting bladder cancer. The technical scheme has the advantages that the copy number amplification can serve as one of biological detection indexes of a molecular probe or a targeting primer for developing the bladder cancer screening kit.

The invention relates to the technical field of biological medicines, and particularly discloses application of a circular RNAcirc0001610 and an expression product thereof in medicines for diagnosing and treating bladder cancer, and the nucleotide sequence of the circular RNAcirc0001610 is as shown in SEQ ID NO: 1. Experiments show that the expression of the circular RNAcirc0001610 and the expression product thereof in bladder cancer tissues is obviously up-regulated. In human bladder cancer cells 5637 and bladder cancer cells J82, the proliferation, migration and invasion levels of the bladder cancer cells are remarkably inhibited by knocking down the expression level of the circular RNAcirc0001610, that is, the growth of bladder cancer cell strains can be inhibited by down-regulating the expression of the circular RNAcirc0001610.

The invention discloses sialidase with metal ion tolerance, heat stability and acid stability. The amino acid sequence of the sialidase is as shown in SEQ ID No. 1 or is an amino acid sequence obtained through deletion and mutation of SEQ ID No. 1 and maintaining unchanged sialidase functions; and the amino acid sequence is purified after expression by Escherichia coli. The sialidase provided by the invention has strong tolerance to divalent metal ions, heat stability and acid stability, can hydrolyze substrates in the connection forms of alpha-2,3 and alpha-2,6 and realizes biotransformation of total gangliosides extracted from pig brains for preparation of high-purity GM1; meanwhile, it is found out for the first time that the sialidase can inhibit migration of bladder cancer cells by transforming ganglioside on the surface of the cancer cells into GM1, so the sialidase has important application prospects.